España -
español -
AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)
sunitinib silver 50 mg cápsulas duras efg
silver pharma s.l. - sunitinib malato - cÁpsula dura - 50 mg - sunitinib malato 50 mg - sunitinib
Unión Europea -
español -
EMA (European Medicines Agency)
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agentes antineoplásicos - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
Cuba -
español -
CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)
sunitinib 50 mg
lotus pharmaceuticals co. ltd - sunitinib (eq. a 66,8 mg de malato de sunitinib) - cápsula - 50 mg
Cuba -
español -
CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)
sunitinib 125 mg
lotus pharmaceuticals co. ltd - sunitinib (eq. a 16,7 mg de malato de sunitinib) - cápsula - 12,5 mg
Cuba -
español -
CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)
sunitinib 25 mg
lotus pharmaceuticals co. ltd - sunitinib (eq. a 33,4 mg de malato de sunitinib) - cápsula - 25 mg
Unión Europea -
español -
EMA (European Medicines Agency)
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agentes antineoplásicos - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
Chile -
español -
ISPC (Instituto de Salud Pública de Chile)
sunitinib cápsulas 50 mg
siron pharma s.p.a. - sunitinib - sin formulas
Chile -
español -
ISPC (Instituto de Salud Pública de Chile)
sunitinib cápsulas 12,5 mg
siron pharma s.p.a. - sunitinib - sin formulas
Chile -
español -
ISPC (Instituto de Salud Pública de Chile)
sunitinib cápsulas 25 mg
siron pharma s.p.a. - sunitinib - sin formulas
Chile -
español -
ISPC (Instituto de Salud Pública de Chile)
sunitinib cápsulas 12,5 mg
logistics business services chile s.p.a. - sunitinib - sin formulas